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Background and Aims: Targeting inflammation is nowadays considered as a
challenging pharmacological strategy to prevent or delay the development of vascular
diseases. Angiotensin-(1-7) is a member of the renin-angiotensin system (RAS) that
binds Mas receptors and has gained growing attention in the last years as a regulator
of vascular homeostasis. Here, we explored the capacity of Ang-(1-7) to counteract
human aortic smooth muscle cell (HASMC) inflammation triggered by RAS-dependent
and -independent stimuli, such as Ang II or interleukin (IL)-1β.
Methods and Results: In cultured HASMC, the expression of inducible nitric oxide
synthase (iNOS) and the release of nitric oxide were stimulated by both Ang II and IL-1β,
as determined by Western blot and indirect immunofluorescence or the Griess method,
respectively. iNOS induction was inhibited by Ang-(1-7) in a concentration-dependent
manner. This effect was equally blocked by two different Mas receptor antagonists, A779
and D-Pro7-Ang-(1-7), suggesting the participation of a unique Mas receptor subtype.
Using pharmacological inhibitors, the induction of iNOS was proven to rely on the
consecutive upstream activation of NADPH oxidase and nuclear factor (NF)-κB. Indeed,
Ang-(1-7) markedly inhibited the activation of the NADPH oxidase and subsequently of
NF-κB, as determined by lucigenin-derived chemiluminescence and electromobility shift
assay, respectively.
Conclusion: Ang-(1-7) can act as a counter-regulator of the inflammation of vascular
smooth muscle cells triggered by Ang II, but also by other stimuli beyond the RAS.
Activating or mimicking the Ang-(1-7)/Mas axis may represent a pharmacological
opportunity to attenuate the pro-inflammatory environment that promotes and sustains
the development of vascular diseases.
Keywords: vascular smooth muscle, inflammation, inducible nitric oxide synthase, angiotensin-(1-7), Mas
receptors, cytokines, interleukin-1β, cell signaling
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INTRODUCTION
Vascular inflammation is a key feature of vascular diseases,
like hypertension or atherosclerosis, which are major causes
of mortality worldwide (Daiber et al., 2016). In the context
of vascular diseases, vasoactive peptides, cytokines, and other
agents, play a pivotal role in promoting vascular inflammation
not only through the early recruitment of circulating leukocytes,
but also during the progression of the disease through
the activation of vascular smooth muscle cells (VSMC)
(Lacolley et al., 2012; Chistiakov et al., 2015). Indeed, activated
VSMC can switch to a pro-inflammatory phenotype that
drives the expression of a wide array of pro-inflammatory
molecules and mediators, which in turn perpetuate and amplify
the deleterious vascular environment (Lacolley et al., 2012;
Chistiakov et al., 2015). In this context, attenuating inflammation,
by pharmacological tools or other approaches, is nowadays
considered as a challenging strategy to prevent or delay the
development of vascular diseases (Everett et al., 2013; Daiber
et al., 2016).
The renin-angiotensin system (RAS) is a key player in the
regulation of cardiovascular homeostasis both in health and
disease. Angiotensin (Ang)-II has been extensively studied over
the last decades in the context of vascular pathophysiology,
where it has proven to play a pivotal role in disrupting vascular
homeostasis and promoting endothelial dysfunction and vascular
remodeling through the activation of AT1 receptors (Balakumar
and Jagadeesh, 2014). Ang II has also been extensively linked to
vascular cell inflammation, through signaling pathways involving
the generation of reactive oxygen species (ROS) and the
activation of the transcription factor nuclear factor (NF)-κB,
among other (Montezano et al., 2014).
While Ang II has been for long acknowledged as the main
biologically active peptide of the RAS, other components of
the RAS have recently gained growing attention. Ang-(1-7) is
a heptapeptide, mainly generated from Ang II through the
action of angiotensin converting enzyme 2 (ACE2) but also from
Ang I via neutral endopeptidase (NEP) activity (Passos-Silva
et al., 2015). Ang-(1-7) is a ligand for the G protein-coupled
receptor Mas (Kostenis et al., 2005). In the vasculature, Ang-
(1-7) has been considered as a physiological antagonist of Ang
II, since it displays vasodilatory, antiangiogenic, antiproliferative,
antimigratory, antiapoptotic, and antihypertrophic properties,
among other (Jiang et al., 2014; Passos-Silva et al., 2015). Several
of these vasculoprotective actions are mainly the result of the
modulation of VSMC function by Ang-(1-7) (Zhang et al., 2010;
Alzayadneh and Chappell, 2014; Bihl et al., 2015). Little is
known, however, on the direct anti-inflammatory properties of
the heptapeptide on this vascular cell type.
In the present study, we evaluated the capacity of Ang-(1-7)
to counteract the pro-inflammatory response triggered by Ang II
in primary human VSMC cultures in terms of NF-κB activation
and inducible nitric oxide synthase (iNOS) induction. Moreover,
we tested the capacity of Ang-(1-7) to dampen inflammation
beyond the RAS, by using the cytokine interleukin (IL)-1β to
activate human VSMC. Finally, we studied the contribution
of Mas receptors subtypes to the actions of Ang-(1-7) and
partly dissected the pro-inflammatory intracellular pathways
modulated by Ang-(1-7) in human VSMC.
MATERIALS AND METHODS
Materials
Culture plastic ware was from TPP (Trasadingen, Switzerland).
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal calf serum
(FCS), and trypsin-EDTA were from Biological industries (Beit-
Hamek, Israel). IL-1β was from Peprotech (London, UK),
while the Mas antagonists A779 and D-Pro7-Ang-(1-7) were
purchased Bachem (Bubendorf, Switzerland) and Biosyntan
(Berlin, Germany), respectively. Anakinra was purchased from
Swedish Orphan Biovitrum AB (Stockholm, Sweden). Ang-(1-
7), Ang II, losartan, apocynin, and pyrrolidine dithiocarbamate
(PDTC) were purchased from Sigma (St. Louis, MO, USA).
Cell Culture
Primary cultures of human aortic smooth muscle cells (HASMC)
were obtained by enzymatic dissociation from aortic fragments
of five organ donors free of vascular disease (two men and
three women, age 35 ± 5.6 years), conforming to the principles
outlined in the Declaration of Helsinki and according to Spanish
legal regulations, as previously described (Romacho et al.,
2009). The study was approved by the Ethics Committee of
Hospital Universitario de Getafe (CEIC 14/17). HASMC from the
different donors were pooled and routinely cultured in DMEM
supplemented with 10% FCS and antibiotics (Romacho et al.,
2009). For experiments, HASMC were deprived of serum for
24 h prior to the addition of different test compounds in serum-
free medium supplemented with 0.1% BSA. Cultures between the
third and the tenth passages were used.
Western Blot
The levels of iNOS were determined by Western blot using a
polyclonal antibody (Transduction Laboratories, Lexington, KY,
USA; dilution 1/1,000), followed by an appropriate secondary
peroxidase-conjugated antibody (Chemicon, Temecula, CA,
USA; dilution 1/10,000), as previously described (Romacho
et al., 2009). Inmunoreactive bands were visualized by enhanced
chemiluminescence detection (Millipore, Billerica, MA, USA),
and quantified using ImageJ free software. For every experiment,
iNOS levels were normalized to α-tubulin using a primary
polyclonal antibody from Sigma (dilution 1/10,000).
Determination of Nitric Oxide Release
Nitric oxide (NO) was indirectly quantified in HASMC
supernatants using the Griess Method, as previously described
(Lafuente et al., 2008). For results normalization, protein content
was determined by the Bradford assay.
Nuclear Extracts and Electromobility
Shift Assay
Nuclear extracts were obtained as described before
(Romacho et al., 2009). For electromobility shift assay
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(EMSA), a commercial oligonucleotide (Promega, Madison,
WI, USA) encoding the NF-κB consensus sequence (5′-
AGTTGAGGGGACTTTCCCAGGC-3′) was 5′-end labeled
using [γ-32P]ATP and T4 polynucleotide kinase (Promega,
Madison, WI, USA). For binding reactions, nuclear extracts
(5 µg) were incubated on ice for 15 min in a reaction
buffer [40 mM HEPES (pH 7.0), 140 mmol/L NaCl, 5 mM
dithiothreitol, 10 µg/mL BSA, 0.01% Nonidet P-40, 4% Ficoll,
and 0.05 µg/mL poly(dI-dC).poly(dI-dC)]. After addition of
the labeled oligonucleotide (∼50,000 cpm) the reaction mix
was further incubated for 20 min at room temperature. For
competition experiments a 100-fold excess of unlabeled doubled-
stranded oligonucleotide was added to the binding reaction.
DNA-protein complexes were resolved on 4% non-denaturing
polyacrylamide gels in 0.5x TBE (45 mmol/L Tris-borate,
1 mM EDTA, pH 8.0) at 4◦C. Gels were dried and exposed
to autoradiography at −80◦C. The intensity of the resulting
bands was quantified by densitometry, as previously described
(Romacho et al., 2009), using Image J free software. The DNA
binding activity of NF-κB was abolished by PDTC (100 µM).
NADPH Oxidase Activity Assay
NADPH oxidase was measured by lucigenin-derived
chemiluminescence, as described previously (Vallejo et al.,
2014). Briefly, HASMC were washed in ice-cold phosphate-
buffered saline, scraped and centrifuged. The resulting cell
pellet was homogenized in lysis buffer (pH 7.0) containing
50 mM KH2PO4, 1 mM EGTA, and 150 mM sucrose. For every
sample, the protein content was determined by the bicinchoninic
acid method. Cell extracts (5 µg protein) were incubated
in phosphate-buffered saline containing 5 µM lucigenin and
100 µM NADPH and luminiscence was then measured every 10 s
for 5 min in a tube luminometer (Optocomp, MGM Instruments,
Hamden, CT, USA). The enzymatic activity, which was sensitive
to the blockade by apocynin (30 µM), was expressed as relative
light units (RLUs)/µg of protein/min.
Statistical Analysis
Results are expressed as mean ± SEM. Statistical analysis was
performed using one-way ANOVA followed by Bonferroni post
hoc test. n denotes the number of independent experiments.
A p-value ≤0.05 was considered statistically significant.
RESULTS
Ang-(1-7) Inhibits the Induction of iNOS
by Ang II and IL-1β
The induction of iNOS, and the subsequent generation of NO
is a major feature of the response of VSMC activated by pro-
inflammatory stimuli (Chistiakov et al., 2015). Figure 1A shows
that exposing HASMC to Ang II (100 nM) for 18 h resulted in a
marked enhancement of iNOS levels, as compared with untreated
cultures. This effect was abolished by the AT1 antagonist
losartan (1 µM), which had no effect on iNOS levels by itself
(Figure 1A). The induction of iNOS by Ang II was inhibited by
Ang-(1-7) (1 nM–1 µM) in a concentration-dependent manner
(Figure 1B).
While Ang-(1-7) has been gradually acknowledged as a
physiological antagonist of Ang II, very little is known about
the capacity of Ang-(1-7) to modulate the pro-inflammatory
responses elicited by RAS-independent agonists. Figure 1C
shows that the pro-inflammatory cytokine IL-1β (2.5 ng/mL)
promoted the induction of iNOS in HASMC, which was
blocked in the presence of the IL1 receptor antagonist anakinra
(1 µg/mL). As for Ang II, Ang-(1-7) was capable to attenuate the
induction of iNOS elicited by IL-1β (Figure 1D). For subsequent
experiments, Ang-(1-7) was used at a fixed concentration of
100 nM.
The Mas Antagonists A779 and
D-Pro-Ang-(1-7) Prevent the Attenuation
of iNOS Induction by Ang-(1-7)
Ang-(1-7) has been described as a ligand for the G-protein-
coupled receptor Mas (Kostenis et al., 2005). In HASMC, the Mas
receptor antagonist D-Ala7-Ang-(1-7) (A779; 1 µM) prevented
the capacity of Ang-(1-7) to attenuate the induction of iNOS
elicited by both Ang II and IL-1β, as shown by Western
blot (Figures 2A,B) and by indirect immunofluorescence
(Figure 2C). Accordingly, A779 also blocked the reduction of NO
release elicited by Ang-(1-7) in cells stimulated with Ang II or IL-
1β (Figures 2D,E). In the absence of Ang II or IL-1β, neither Ang-
(1-7) nor A779 did modify by themselves iNOS levels (Figure 2B)
or NO release (3.12 ± 0.93 and 2.98 ± 1.06 nmol/mg protein,
respectively; n= 3–5).
The existence of several Mas receptor subtypes in the
vasculature has been previously suggested based on the
differential capacity of two Mas receptors blockers A779 and
D-Pro7-Ang-(1-7) to fully counteract some biological actions of
Ang-(1-7), such as vasodilation (Silva et al., 2007). In HASMC
cultures, however, D-Pro7-Ang-(1-7) also blocked the inhibitory
effects of Ang-(1-7) on iNOS induction (Figures 2F,G). D-Pro7-
Ang-(1-7) alone did not modify iNOS levels (Figure 2G).
Ang-(1-7) Prevents NF-κB Activation
To gain insight into the signaling pathways influenced by Ang-
(1-7), we next focused on NF-κB, as a pivotal transcription
factor regulating the expression of inflammation-related proteins,
including iNOS (Brasier, 2010). Both Ang II and IL-1β promoted
the activation of NF-κB (Figures 3A,B). This step that was
necessary for the downstream induction of iNOS, since the NF-
κB inhibitor PDTC abolished iNOS induction (Figures 3C,D).
Ang-(1-7) was capable to attenuate NF-κB activation, and this
effect was blocked by A779 (Figures 3A,B).
Ang-(1-7) Inhibits the Stimulation of
NADPH Oxidase Activity
NF-κB is a redox-sensitive factor that can be regulated by
different sources of ROS. Among these, NADPH oxidase is
a major ROS-generating enzyme in vascular cells and its
over-activation has been linked to vascular damage (Nguyen
Dinh Cat et al., 2013). Figures 4A,B show that Ang-(1-7)
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FIGURE 1 | Ang-(1-7) inhibits inducible nitric oxide synthase (iNOS) induction elicited by Ang II or IL-1β in human aortic smooth muscle cells
(HASMC). (A) HASMC were stimulated with Ang II (100 nM) alone or in the presence of the AT1 receptor antagonist losartan (1 µM) for 18 h, after which iNOS levels
were determined by Western blot and normalized to α-tubulin. (B) In another set of experiments, the impact of increasing concentrations of Ang-(1-7) (1 nM–1 µM)
on iNOS induction by Ang II was tested. (C) The pro-inflammatory cytokine IL-1β (2.5 ng/mL) promoted iNOS induction, which was prevented by the IL1 receptor
blocker anakinra (1 µg/mL). (D) As for Ang II, Ang-(1-7) prevented the induction of iNOS by IL-1β in a concentration-dependent manner. Results are expressed as
mean ± SEM; n = 5. Representative blots are shown in the corresponding panels. ∗p < 0.05 vs. untreated cultures, #p < 0.05 vs. Ang II- or IL-1β-treated cultures,
respectively.
was able to attenuate the stimulation of NADPH oxidase
activity triggered by both Ang II and IL-1β in HASMC. The
use of the antioxidant NADPH oxidase inhibitor apocynin
revealed that NADPH oxidase activity was necessary for the
consecutive downstream NF-κB activation (Figures 3A,B) and
iNOS induction (Figures 4C,D) elicited by Ang II and IL-1β.
DISCUSSION
Since inflammation is at the basis of a wide array of
cardiovascular diseases, the identification of pharmacological
tools to prevent or attenuate vascular cell inflammation has
gained growing attention over the last years (Natarajan and
Cannon, 2010). In this study, we have identified Ang-(1-7) as
a novel player in preventing the pro-inflammatory activation
of human VSMC. More specifically, Ang-(1-7) attenuated the
induction of iNOS, a NO-generating enzyme that is found over-
activated in a series of vascular diseases running with low grade
inflammation, such as atherosclerosis, hypertension or diabetic
vasculopathy (Shimokawa and Tsutsui, 2010; Di Pietro et al.,
2013; Oliveira-Paula et al., 2014).
Over a decade ago, Mas was identified as the main receptor
mediating the biological actions of Ang-(1-7) (Santos et al., 2003).
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FIGURE 2 | The inhibition of iNOS induction mediated by Ang-(1-7) is dependent on Mas receptors. After exposing HASMC for 18 h to (A) Ang II (100 nM)
or (B) IL-1β (2.5 ng/mL) with or without 100 nM Ang-(1-7), iNOS levels were determined by Western blot. In some experiments, cells were pre-incubated with the
Mas receptor antagonist A779 (1 µM). (C) iNOS levels (red) were also determined by indirect immunofluorescence in response to the different stimuli. Nuclei were
counterstained with DAPI (blue) (400×). In another set of experiments, nitric oxide (NO) production was determined in the supernatants of HASMC exposed for 18 h
to Ang II (D) or IL-1β (E), with or without Ang-(1-7) and A779. The Mas receptor antagonist D-Pro7-Ang-(1-7) (1 µM) was also capable to block the inhibitory effect of
Ang-(1-7) on iNOS induction by Ang II (F) or IL-1β (G). Results are expressed as mean ± SEM; n = 5. Representative blots are shown in the corresponding panels.
∗p < 0.05 vs untreated cultures, #p < 0.05 vs Ang II- or IL-1β-treated cultures, respectively.
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FIGURE 3 | Ang-(1-7) reduces NF-κB activation via Mas receptors in HASMC. The activation of NF-κB induced after 18 h incubation with (A) Ang II (100 nM)
or (B) IL-1β (2.5 ng/mL) was blunted by the antioxidant NADPH oxidase inhibitor apocynin (30 µM) and significantly reduced by Ang-(1-7) (100 nM), as determined
by EMSA. The effect of Ang-(1-7) was prevented by the Mas receptor antagonist A779 (1 µM). The induction of iNOS by Ang II (C) or IL-1β (D) was abolished by the
NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) (100 µM). Representative blot or EMSA images are shown in the corresponding panels. Results are expressed as
mean ± SEM; n = 4. ∗p < 0.05 vs untreated cultures, #p < 0.05 vs Ang II- or IL-1β-treated cultures, respectively.
The Mas proto-oncogene encodes a 7 transmembrane protein
exhibiting features of G-protein coupled receptors (Santos et al.,
2003). In the vasculature, the presence of more than one
subtype of Mas receptors was proposed by Silva et al. (2007)
based on the capacity of D-Pro7-Ang-(1-7), but not of A779,
to inhibit Ang-(1-7)-mediated vasodilation in rat aortas (Silva
et al., 2007). More recently, an acute lung injury model has
also pointed out the existence of more than one type of Mas
receptors in the respiratory system (Klein et al., 2013). In
contrast, we observed that D-Pro7-Ang-(1-7) and A779 were
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FIGURE 4 | Ang-(1-7) reduces NADPH oxidase activity via Mas receptors. In HASMC, Ang-(1-7) (100 nM) reduced the stimulation of NADPH oxidase
observed after 18 h incubation with (A) Ang II (100 nM) or (B) IL-1β (2.5 ng/mL), and this effect was blocked by the Mas receptor antagonist A779 (1 µM). The
inhibition of NADPH oxidase by the antioxidant inhibitor apocynin (30 µM) prevented the induction of iNOS by Ang II (C) or IL-1β (D). Representative blots are shown
in the corresponding panels. The NADPH oxidase activity is given as relative light units (RLUs)/µg protein/min. Results are expressed as mean ± SEM; n = 4.
∗p < 0.05 vs untreated cultures, #p < 0.05 vs Ang II- or IL-1β-treated cultures, respectively.
equivalent in blocking the effects of Ang-(1-7). This rather
indicates that both antagonists target the same receptor in
human VSMC and that a unique Mas subtype receptor thus
mediates the anti-inflammatory effects of Ang-(1-7) in this
cell type. Indeed, our findings are in line with other reports
identifying a single Mas receptor, sensitive to both D-Pro7-
Ang-(1-7) and A779 antagonism, mediating the vasorelaxant
action of Ang-(1-7) in murine conductance and resistance
arteries (Lemos et al., 2005; Peiró et al., 2013) as well as
other non-vascular actions of the heptapeptide (Zhao et al.,
2015).
Through its binding to Mas receptors, Ang-(1-7) attenuated
the Ang II-stimulated induction of iNOS in human VSMC.
Indeed, the ACE2/Ang-(1-7) axis is nowadays regarded as an
endogenous counterpart for ACE/Ang II axis, and is thus
considered to play a key role in regulating and limiting the
actions of a central player in cardiovascular physiopathology
such as Ang II. In the cardiovascular system, Ang-(1-7) has
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FIGURE 5 | Schematic diagram of the proposed action of the Ang-(1-7)/Mas axis on HAMSC pro-inflammatory signaling. The binding of Ang II or IL-1β
to their respective membrane receptors results in NADPH oxidase activation, which consecutively leads to NF-κB activation, iNOS induction and NO release.
Through an effect mediated by Mas receptors, Ang-(1-7) promotes NADPH oxidase inhibition and thus attenuates the pro-inflammatory signaling triggered by Ang II,
but also by other non-RAS inflammatory stimuli, such as IL-1β.
proven to counterbalance the vasoconstrictor, pro-oxidant, pro-
fibrotic, and hypertrophic actions of Ang II (Grobe et al., 2007;
McCollum et al., 2012). We now demonstrate that Ang-(1-7) may
also protect against VSMC inflammation elicited by the main
biologically active peptide of the RAS.
However, one of the major findings of the present study is
that the Ang-(1-7)/Mas axis not only counteracts the action
of Ang II, but is also acts as an anti-inflammatory compound
beyond the RAS. Pro-inflammatory cytokines, including IL-1β,
are key contributors to the low-grade inflammatory environment
that characterizes a wide array of vascular diseases (Ridker,
2016). Indeed, high sensitivity C-reactive protein, used as a
biomarker of cardiovascular risk, is now being considered as
a downstream surrogate marker of upstream IL-1β activity
(Ridker, 2016). From a pharmacological perspective, drugs
targeted against IL-1β and its receptors, initially used to treat
non-vascular inflammatory conditions, are now being assayed
as vasculoprotective and anti-atherothrombotic tools (Ridker,
2016). In the present study, the stimulation of Ang-(1-7)/Mas
axis revealed itself as an alternate strategy to minimize the
impact of IL-1β on human VSMC pro-inflammatory activation.
This is in line with other reports showing that in the context
of neuroinflammation the pharmacological activation of the
ACE2/Ang-(1-7) can reduce the inflammatory response of
human retinal pigment epitelial cells to lipopolysaccharide
(Tao et al., 2016). Furthermore, Ang-(1-7) may prevent the
inflammation induced in astrocytes by physical stressors, such as
radiation (Moore et al., 2013).
To further understand the mechanisms underlying the anti-
inflammatory action of Ang-(1-7), the focus was set on common
signaling pathways activated by both Ang II and IL-1β. The
transcription factor NF-κB is a main redox-sensitive regulator
of iNOS expression (Teng et al., 2002; Zahradka et al., 2002),
and its over-activation by a wide array of stimuli has been
associated to chronic inflammatory vascular diseases, such as
atherosclerosis (Monaco et al., 2004). Upstream of NF-κB,
Ang-(1-7) promoted the inhibition of NADPH oxidase and
diminished ROS generation, which in turn led to a marked
attenuation of the NF-κB/iNOS axis and thus of human VSMC
activation (Figure 5). This is in line with other reports showing
that Ang-(1-7) negatively regulates NADPH oxidase activation
elicited by Ang II in endothelial cells (Sampaio et al., 2007;
Xiao et al., 2015) or other non-vascular cell types, such as
skeletal muscle or kidney tubular cells, among other (Kim
et al., 2012; Morales et al., 2014). The activation of the IP3/Akt
pathway, one of most relevant Mas-related signaling events
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acknowledged to date (Bader et al., 2014), might be on the
basis of the protective effect of Ang-(1-7) against NOX-derived
ROS formation and apoptosis in cerebral endothelial cells
(Xiao et al., 2015). In embryonic pancreatic explants, however,
Ang-(1-7) rather seems to activate NADPH oxidase (Wang
et al., 2015), which indicates that the precise mechanisms
linking Mas activation and NADPH oxidase activity may
be complex and still remain to be explored more in depth.
Overall, our findings show that the inhibition of NADPH
oxidase activity appears as a pivotal common intracellular
target of Ang-(1-7) in protecting against inflammation
triggered by stimuli of different nature. This mechanism
might indeed be on the basis of the beneficial action of the
heptapeptide on experimental atherosclerosis plaque formation
(Yang et al., 2015). Whether Ang-(1-7) can modulate other
ROS sources and total redox balance remains to be further
explored.
Over the last years, pharmacological research has been
undertaken to identify valuable tools to regulate the ACE2/Ang-
(1-7)/Mas axis, with particular focus on Ang-(1-7) mimetics
and ACE2 activity modulators (Fraga-Silva et al., 2013; Simões
e Silva et al., 2013). This study supports that activating or
mimicking the ACE2/Ang-(1-7)/Mas axis may represent a
valuable pharmacological opportunity to attenuate the pro-
inflammatory environment that promotes and sustains the
development of vascular diseases.
AUTHOR CONTRIBUTIONS
CP and CS-F designed the experiments. LV, EC, AR and SV
generated experimental data. CP, CS-F, LV, EC, AS-L, AR, and
MR-G analyzed raw data and performed statistical analysis. LV,
AH-L, AR and EC drew the figures. CP and CS-F wrote the
manuscript. LV, SV, TR and RC contributed in discussion and
reviewed the manuscript.
FUNDING
This work was funded by grants from Ministerio de Economía y
Competitividad (SAF2014-52762-R).
REFERENCES
Alzayadneh, E. M., and Chappell, M. C. (2014). Angiotensin-(1-7) abolishes AGE-
induced cellular hypertrophy and myofibroblast transformation via inhibition
of ERK1/2. Cell. Signal. 26, 3027–3035. doi: 10.1016/j.cellsig.2014.09.010
Bader, M., Alenina, N., Andrade-Navarro, M. A., and Santos, R. A. (2014). MAS
and its related G protein-coupled receptors, Mrgprs. Pharmacol. Rev. 66,
1080–1105. doi: 10.1124/pr.113.008136
Balakumar, P., and Jagadeesh, G. (2014). A century old renin-angiotensin system
still grows with endless possibilities: AT1 receptor signaling cascades in
cardiovascular physiopathology. Cell. Signal. 26, 2147–2160. doi: 10.1016/j.
cellsig.2014.06.011
Bihl, J. C., Zhang, C., Zhao, Y., Xiao, X., Ma, X., Chen, Y., et al. (2015). Angiotensin-
(1-7) counteracts the effects of Ang II on vascular smooth muscle cells, vascular
remodeling and hemorrhagic stroke: role of the NF-κB inflammatory pathway.
Vascul. Pharmacol. 73, 115–123. doi: 10.1016/j.vph.2015.08.007
Brasier, A. R. (2010). The nuclear factor-kappaB-interleukin-6 signalling pathway
mediating vascular inflammation. Cardiovasc. Res. 86, 211–218. doi: 10.1093/
cvr/cvq076
Chistiakov, D. A., Orekhov, A. N., and Bobryshev, Y. V. (2015). Vascular smooth
muscle cell in atherosclerosis. Acta Physiol. (Oxf.). 214, 33–50. doi: 10.1111/
apha.12466
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I.,
et al. (2016). Targeting vascular (endothelial) dysfunction. Br. J. Pharmacol
doi: 10.1111/bph.13517 [Epub ahead of print].
Di Pietro, N., Di Tomo, P., Di Silvestre, S., Giardinelli, A., Pipino, C., Morabito, C.,
et al. (2013). Increased iNOS activity in vascular smooth muscle cells from
diabetic rats: potential role of Ca(2+)/calmodulin-dependent protein kinase II
delta 2 (CaMKIIδ(2)). Atherosclerosis. 226, 88–94. doi: 10.1016/j.atherosclerosis.
2012.10.062
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., Macfadyen, J.,
Zaharris, E., et al. (2013). Rationale and design of the cardiovascular
inflammation reduction trial: a test of the inflammatory hypothesis of
atherothrombosis. Am. Heart J. 166, 199–207. doi: 10.1016/j.ahj.2013.
03.018
Fraga-Silva, R. A., Ferreira, A. J., and Dos Santos, R. A. (2013). Opportunities for
targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor
pathway in hypertension. Curr. Hypertens. Rep. 15, 31–38. doi: 10.1007/s11906-
012-0324-1
Grobe, J. L., Mecca, A. P., Lingis, M., Shenoy, V., Bolton, T. A., Machado, J. M.,
et al. (2007). Prevention of angiotensin II-induced cardiac remodeling by
angiotensin-(1-7). Am. J. Physiol. Heart Circ. Physiol. 292, H736–H742. doi:
10.1152/ajpheart.00937.2006
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., et al. (2014).
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic
targets. Nat. Rev. Cardiol. 11, 413–426. doi: 10.1038/nrcardio.2014.59
Kim, S. M., Kim, Y. G., Jeong, K. H., Lee, S. H., Lee, T. W., Ihm, C. G., et al.
(2012). Angiotensin II-induced mitochondrial Nox4 is a major endogenous
source of oxidative stress in kidney tubular cells. PLoS ONE 7:e39739. doi:
10.1371/journal.pone.0039739
Klein, N., Gembardt, F., Supé, S., Kaestle, S. M., Nickles, H., Erfinanda, L., et al.
(2013). Angiotensin-(1-7) protects from experimental acute lung injury. Crit.
Care Med. 41, e334–e343. doi: 10.1097/CCM.0b013e31828a6688
Kostenis, E., Milligan, G., Christopoulos, A., Sanchez-Ferrer, C. F., Heringer-
Walther, S., Sexton, P. M., et al. (2005). G-protein-coupled receptor Mas is a
physiological antagonist of the angiotensin II type 1 receptor. Circulation. 111,
1806–1813. doi: 10.1161/01.CIR.0000160867.23556.7D
Lacolley, P., Regnault, V., Nicoletti, A., Li, Z., and Michel, J. B. (2012). The vascular
smooth muscle cell in arterial pathology: a cell that can take on multiple roles.
Cardiovasc. Res. 95, 194–204. doi: 10.1093/cvr/cvs135
Lafuente, N., Matesanz, N., Azcutia, V., Romacho, T., Nevado, J., Rodríguez-
Mañas, L., et al. (2008). The deleterious effect of high concentrations of
D-glucose requires pro-inflammatory preconditioning. J. Hypertens. 26, 478–
485. doi: 10.1097/HJH.0b013e3282f331fb
Lemos, V. S., Silva, D. M., Walther, T., Alenina, N., Bader, M., and Santos,
R. A. (2005). The endothelium-dependent vasodilator effect of the nonpeptide
Ang (1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice.
J. Cardiovasc. Pharmacol. 46, 274–279. doi: 10.1097/01.fjc.0000175237.41573.63
McCollum, L. T., Gallagher, P. E., and Ann Tallant, E. (2012). Angiotensin-
(1-7) attenuates angiotensin II-induced cardiac remodeling associated with
upregulation of dual-specificity phosphatase 1. Am. J. Physiol. Heart Circ.
Physiol. 302, H801–H810. doi: 10.1152/ajpheart.00908.2011
Monaco, C., Andreakos, E., Kiriakidis, S., Mauri, C., Bicknell, C., Foxwell, B., et al.
(2004). Canonical pathway of nuclear factor κ B activation selectively regulates
proinflammatory and prothrombotic responses in human atherosclerosis. Proc.
Natl. Acad. Sci U.S.A. 10, 5634–5639. doi: 10.1073/pnas.0401060101
Montezano, A. C., Nguyen Dinh Cat, A., Rios, F. J., and Touyz, R. M. (2014).
Angiotensin II and vascular injury. Curr. Hypertens. Rep. 16, 431. doi: 10.1007/
s11906-014-0431-2
Moore, E. D., Kooshki, M., Metheny-Barlow, L. J., Gallagher, P. E., and Robbins,
M. E. (2013). Angiotensin-(1-7) prevents radiation-induced inflammation
in rat primary astrocytes through regulation of MAP kinase signaling.
Frontiers in Pharmacology | www.frontiersin.org 9 December 2016 | Volume 7 | Article 482
fphar-07-00482 December 14, 2016 Time: 11:33 # 10
Villalobos et al. Angiotensin-(1-7) Counteracts VSMC Inflammatory Signaling
Free Radic. Biol. Med. 65, 1060–1068. doi: 10.1016/j.freeradbiomed.2013.
08.183
Morales, M. G., Abrigo, J., Meneses, C., Simon, F., Cisternas, F., Rivera, J. C., et al.
(2014). The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of
TGF-β1 induced by AngII in mouse skeletal muscle. Clin. Sci. (Lond.) 127,
251–264. doi: 10.1042/CS20130585
Natarajan, P., and Cannon, C. P. (2010). Could direct inhibition of
inflammation be the “next big thing” in treating atherosclerosis?
Arterioscler. Thromb. Vasc. Biol. 30, 2081–2083. doi: 10.1161/ATVBAHA.110.
213793
Nguyen Dinh Cat, A., Montezano, A. C., Burger, D., and Touyz, R. M.
(2013). Angiotensin II, NADPH oxidase, and redox signaling in the
vasculature. Antioxid. Redox Signal. 19, 1110–1120. doi: 10.1089/ars.2012.
4641
Oliveira-Paula, G. H., Lacchini, R., and Tanus-Santos, J. E. (2014). Inducible nitric
oxide synthase as a possible target in hypertension. Curr. Drug Targets. 15,
164–174. doi: 10.2174/13894501113146660227
Passos-Silva, D. G., Brandan, E., and Santos, R. A. (2015). Angiotensins as
therapeutic targets beyond heart disease. Trends Pharmacol. Sci. 36, 310–320.
doi: 10.1016/j.tips.2015.03.001
Peiró, C., Vallejo, S., Gembardt, F., Palacios, E., Novella, S., Azcutia, V., et al.
(2013). Complete blockade of the vasorelaxant effects of angiotensin-
(1-7) and bradykinin in murine microvessels by antagonists of the
receptor Mas. J. Physiol. 59, 2275–2285. doi: 10.1113/jphysiol.2013.
251413
Ridker, P. M. (2016). From C-reactive protein to interleukin-6 to interleukin-1:
moving upstream to identify novel targets for atheroprotection. Circ. Res. 118,
145–156. doi: 10.1161/CIRCRESAHA.115.306656
Romacho, T., Azcutia, V., Vázquez-Bella, M., Matesanz, N., Cercas, E., Nevado, J.,
et al. (2009). Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory
signalling in human vascular smooth muscle cells through nicotinamide
phosphoribosyltransferase activity. Diabetology 52, 2455–2463. doi: 10.1007/
s00125-009-1509-2
Sampaio, W. O., Henrique de Castro, C., Santos, R. A., Schiffrin, E. L.,
and Touyz, R. M. (2007). Angiotensin-(1-7) counterregulates angiotensin II
signaling in human endothelial cells. Hypertension 50, 1093–1098. doi: 10.1161/
HYPERTENSIONAHA.106.084848
Santos, R., Simoes e Silva, A., Maric, C., Silva, D., Machado, R., de Buhr, I., et al.
(2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled
receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258–8263. doi: 10.1073/pnas.
1432869100
Shimokawa, H., and Tsutsui, M. (2010). Nitric oxide synthases in the pathogenesis
of cardiovascular disease: lessons from genetically modified mice. Pflugers Arch.
459, 959–967. doi: 10.1007/s00424-010-0796-2
Silva, D. M., Vianna, H. R., Cortes, S. F., Campagnole-Santos, M. J., Santos, R. A.,
and Lemos, V. S. (2007). Evidence for a new angiotensin-(1-7) receptor subtype
in the aorta of Sprague-Dawley rats. Peptides. 28, 702–707. doi: 10.1016/j.
peptides.2006.10.007
Simões e Silva, A. C., Silveira, K. D., Ferreira, A. J., and Teixeira, M. M. (2013).
ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.
Br. J. Pharmacol 169, 477–492. doi: 10.1111/bph.12159
Tao, L., Qiu, Y., Fu, X., Lin, R., Lei, C., Wang, J., et al. (2016).
Angiotensin-converting enzyme 2 activator diminazene aceturate prevents
lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-κB
pathways in human retinal pigment epithelium. J. Neuroinflammation 13, 35.
doi: 10.1186/s12974-016-0489-7
Teng, X., Zhang, H., Snead, C., and Catravas, J. D. (2002). Molecular mechanisms
of iNOS induction by IL-1 beta and IFN-gamma in rat aortic smooth muscle
cells. Am. J. Physiol. Cell. Physiol. 282, C144–C152.
Vallejo, S., Palacios, E., Romacho, T., Villalobos, L., Peiró, C., and Sánchez-
Ferrer, C. F. (2014). The interleukin-1 receptor antagonist anakinra improves
endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc.
Diabetol. 13, 158. doi: 10.1186/s12933-014-0158-z
Wang, L., Liang, J., and Leung, P. S. (2015). The ACE2/Ang-(1-7)/Mas axis
regulates the development of pancreatic endocrine cells in mouse embryos.
PLoS ONE 10:e0128216. doi: 10.1371/journal.pone.0128216
Xiao, X., Zhang, C., Ma, X., Miao, H., Wang, J., Liu, L., et al. (2015). Angiotensin-(1-
7) counteracts angiotensin II-induced dysfunction in cerebral endothelial cells
via modulating Nox2/ROS and PI3K/NO pathways. Exp. Cell Res. 336, 58–65.
doi: 10.1016/j.yexcr.2015.06.010
Yang, J., Sun, Y., Dong, M., Yang, X., Meng, X., Niu, R., et al. (2015). Comparison
of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque
formation in apolipoprotein E knockout mice. Atherosclerosis 240, 544–549.
doi: 10.1016/j.atherosclerosis.2015.02.055
Zahradka, P., Werner, J. P., Buhay, S., Litchie, B., Helwer, G., and Thomas, S.
(2002). NF-kappaB activation is essential for angiotensin II-dependent
proliferation and migration of vascular smooth muscle cells. J. Mol. Cell.
Cardiol. 34, 1609–1621. doi: 10.1006/jmcc.2002.2111
Zhang, F., Hu, Y., Xu, Q., and Ye, S. (2010). Different effects of angiotensin II and
angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration.
PLoS ONE 5:e12323. doi: 10.1371/journal.pone.0012323
Zhao, Y., Qin, Y., Liu, T., and Hao, D. (2015). Chronic nerve injury-induced Mas
receptor expression in dorsal root ganglion neurons alleviates neuropathic pain.
Exp. Ther. Med. 10, 2384–2388.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Villalobos, San Hipólito-Luengo, Ramos-González, Cercas, Vallejo,
Romero, Romacho, Carraro, Sánchez-Ferrer and Peiró. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 December 2016 | Volume 7 | Article 482
